Curis

CRIS NASDAQ
1.660
+0.050
+3.10%
Closed 16:00 06/20 EDT
Open
1.620
Prev Close
1.610
High
1.700
Low
1.550
Volume
194.64K
Avg Vol (3M)
565.80K
52 Week High
2.650
52 Week Low
0.6000
% Turnover
0.59%
Market Cap
55.03M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Curis CRIS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
MORE >

Recently

Name
Price
%Change